How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

This is the fifth installment of the mathematics series. In the first article, “Fermat Test — Another Principle of Primality ...

Researchers from the National University of Singapore, A*STAR, and the Australian National University have demonstrated a ...

Researchers have replaced trial-and-error tuning of a recursive least squares identifier with a hill-climbing algorithm and a ...

Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- "Artificial Intelligence in Drug Discovery Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ...

We introduce Multi-Agent Self-Supervision (MASS). One shared model solves tasks through a team of virtual subagents, searches for better multi-agent workflows, then uses its own judgments to select ...

A new open-source package called Varmapack simulates VARMA time series exactly from the first observation, eliminating ...

The Relative Strength Index (RSI), a widely adopted momentum indicator in technical analysis, has recently sparked heated new ...

OpenSSH 10.6 disables LZ77 compression, refuses some usernames and plans more frequent releases after AI-found bugs resurfaced.

According to KyeGomezB, P Zero Research reports AI research taste doubled every 3 months since Dec 2025, surpassing expert baseline.

Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.

Richard Socher, co-founder and CEO of Recursive, argues on the Peter Diamandis podcast that while weak forms of recursive self-improvement ...